Akademik Veri Yönetim Sistemi
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.22, sa.3, ss.262-267, 2012 (SCI-Expanded, TRDizin)
Escitalopram treatment in preschool children with anxiety disorders: a case series Objective: To provide data about the efficacy and tolerability of escitalopram treatment in preschool children with anxiety disorders. Methods: This study is a retrospective chart review of preschool children with anxiety disorders treated with escitalopram. Medical records of the subjects were reviewed for sociodemographic features, DSM-IV diagnoses, improvement and treatment related side effects. Clinical-Global Impression-severity (CGI-S) and improvement (CGI-I) scales were used to assess symptom severity and improvement. Results: The subjects were eight girls and three boys (age range 47 to 64 months; 55.45 +/- 5.90). Individual doses of escitalopram ranged between 2-10 mg/day (3.72 +/- 2.49). Five subjects showed mild to very much improvement in obsessive-compulsive symptoms on the CGI-I scale. Three subjects showed moderate to much improvement in anxiety symptoms and three subjects showed mild to much improvement in post-traumatic symptoms. Two subjects (18.18%) did not report any side effects. The most frequently reported side effects were symptoms of behavioral disinhibiton (n=5; 45.45%). The medication was discontinued in three subjects (27.27%) due to side effects, mainly symptoms of behavioral disinhibiton. Conclusions: A cautious trial of escitalopram may be helpful in preschool children with anxiety disorders with significant impairment and/or who are non-responsive to psychosocial interventions. Preschool children may be more vulnerable to develop side effects, particularly behavioral disinhibition.